Pål Erik Gustav Stenmark

Title: Pål Erik Gustav Stenmark: Innovator in Botulinum Neurotoxin Research

Introduction

Pål Erik Gustav Stenmark is a notable inventor based in Järfälla, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of engineered botulinum neurotoxins. With a total of 3 patents to his name, Stenmark's work has implications for both medical and pharmaceutical applications.

Latest Patents

Stenmark's latest patents focus on engineered botulinum neurotoxin (BoNT) polypeptides. These innovations include a modified receptor binding domain of serotype B (B-H), which comprises various substitution mutations. Specific mutations disclosed in his patents include V1118M, Y1183M, E1191M, E1191I, E1191Q, E1191T, S1199Y, S1199F, S1199L, and S1201V. The patents also detail combinations of these mutations, such as E1191M and S1199L, as well as pharmaceutical compositions and methods for their use.

Career Highlights

Throughout his career, Stenmark has worked with prestigious institutions, including Harvard College and Harvard Corporation. His research has contributed to advancements in understanding and utilizing botulinum neurotoxins for therapeutic purposes.

Collaborations

Stenmark has collaborated with notable colleagues in his field, including Min Dong and Lisheng Peng. Their combined expertise has furthered the research and development of innovative biotechnological solutions.

Conclusion

Pål Erik Gustav Stenmark is a prominent figure in the field of biotechnology, particularly known for his work on engineered botulinum neurotoxins. His patents and collaborations reflect a commitment to advancing medical science and improving therapeutic options.